PCSK9 Antibody (YA5417)

Cat. No.: HY-P85725: Data Sheet COA
SDS
User Guide for Antibodies
FAQs
Technical Support

PCSK9 Antibody (YA5417) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PCSK9.

For research use only. We do not sell to patients.

Size	Stock	Quantity
10 μL	In-stock	Estimated Time of Arrival: December 31
50 μL	In-stock	Estimated Time of Arrival: December 31
100 μL	In-stock	Estimated Time of Arrival: December 31
250 μL	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

PCSK9 Antibody (YA5417) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PCSK9.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Observed band size: 74 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

Q8NBP7

Gene ID

255738 [NCBI]

Immunogen

Synthesized peptide derived from human PCSK9

Application &
Dilution Ratio

Application	Dilution Ratio
IHC1	50-200

Purity	affinity chromatography.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:17461796, PubMed:18197702, PubMed:18799458, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways

Subcellular Localization：Cytoplasm; Secreted; Endosome; Lysosome; Cell surface; Endoplasmic reticulum; Golgi apparatus

Expression：
Tissue_specificity:It is expressed in neuroepithelial tumors, colon cancers, hepatocytes, pancreatic cell lines, and Schwann cells.

Isoforms & Post-Translational Modification：Q8NBP7 has 2 isomers: Q8NBP7-1: 74286 Da (predicted); Q8NBP7-2: 20827 Da (predicted).
Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation;Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein;Phosphorylation protects the propeptide against proteolysis

Subunit：Monomer. Can self-associate to form dimers and higher multimers which may have increased LDLR degrading activity. The precursor protein but not the mature protein may form multimers. Interacts with APOB, VLDLR, LRP8/APOER2 and BACE1. The full-length immature form (pro-PCSK9) interacts with SCNN1A, SCNN1B and SCNN1G. The pro-PCSK9 form (via C-terminal domain) interacts with LDLR. Interacts (via the C-terminal domain) with ANXA2 (via repeat Annexin 1); the interaction inhibits the degradation of LDLR (PubMed:18799458)

Synonyms

Proprotein convertase subtilisin/kexin type 9; Neural apoptosis-regulated convertase 1; NARC-1; Proprotein convertase 9; PC9; Subtilisin/kexin-like protease PC9;

Documentation

Select Batch:

Data Sheet (234 KB) SDS (251 KB)

COA (205 KB)

User Guide for Antibodies (1077 KB)